Clinical Trial Update: Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 safety and pharmacodynamic study of sotagliflozin in hemodynamically stable patients with worsening heart failure was terminated; results posted in 2021…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Sotagliflozin (sotagliflozin)

Snippet

Sponsor: Lexicon Pharmaceuticals | Conditions: Cardiac Failure Aggravated | Phase 2 | Status: TERMINATED | Results posted: 2021-05-11